AU2013243388B2 - Methods and compositions for increasing red blood cells - Google Patents

Methods and compositions for increasing red blood cells Download PDF

Info

Publication number
AU2013243388B2
AU2013243388B2 AU2013243388A AU2013243388A AU2013243388B2 AU 2013243388 B2 AU2013243388 B2 AU 2013243388B2 AU 2013243388 A AU2013243388 A AU 2013243388A AU 2013243388 A AU2013243388 A AU 2013243388A AU 2013243388 B2 AU2013243388 B2 AU 2013243388B2
Authority
AU
Australia
Prior art keywords
polypeptide
bmp9
bmp
www
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013243388A
Other languages
English (en)
Other versions
AU2013243388A1 (en
Inventor
John Knopf
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of AU2013243388A1 publication Critical patent/AU2013243388A1/en
Application granted granted Critical
Publication of AU2013243388B2 publication Critical patent/AU2013243388B2/en
Priority to AU2018202326A priority Critical patent/AU2018202326B2/en
Priority to AU2021201196A priority patent/AU2021201196A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013243388A 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells Ceased AU2013243388B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018202326A AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261621154P 2012-04-06 2012-04-06
US61/621,154 2012-04-06
PCT/US2013/035305 WO2013152213A1 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202326A Division AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells

Publications (2)

Publication Number Publication Date
AU2013243388A1 AU2013243388A1 (en) 2014-10-23
AU2013243388B2 true AU2013243388B2 (en) 2018-01-25

Family

ID=49301055

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013243388A Ceased AU2013243388B2 (en) 2012-04-06 2013-04-04 Methods and compositions for increasing red blood cells
AU2018202326A Ceased AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A Abandoned AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018202326A Ceased AU2018202326B2 (en) 2012-04-06 2018-04-03 Methods and compositions for increasing red blood cells
AU2021201196A Abandoned AU2021201196A1 (en) 2012-04-06 2021-02-24 Methods and compositions for increasing red blood cells

Country Status (6)

Country Link
US (4) US9809636B2 (enExample)
EP (2) EP3351260B1 (enExample)
JP (4) JP6234993B2 (enExample)
AU (3) AU2013243388B2 (enExample)
CA (1) CA2869474C (enExample)
WO (1) WO2013152213A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809636B2 (en) 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
GB201412290D0 (en) 2014-07-10 2014-08-27 Cambridge Entpr Ltd Novel use
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
EP3370754B1 (en) 2015-11-04 2026-04-29 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2017296040C1 (en) 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015383A2 (en) * 2006-07-29 2008-02-07 University College Cardiff Consultants Limited Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
CA2157387C (en) * 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
ATE265529T1 (de) 1993-05-12 2004-05-15 Inst Genetics Llc Bmp-10 zusammensetzungen
US6034062A (en) 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
WO2005113590A2 (en) 2004-05-12 2005-12-01 Acceleron Pharma Inc. Bmp10 propeptides and related methods
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
JP2008534607A (ja) * 2005-03-30 2008-08-28 ワイス Ｂｍｐを投与することによって毛髪の成長を刺激するための方法
BRPI0618947B1 (pt) 2005-11-23 2022-07-19 Acceleron Pharma Inc Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
CA2672758C (en) 2006-12-18 2019-07-30 Acceleron Pharma Inc. Activin-actrii antagonists and uses for increasing red blood cell levels
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es) 2007-02-09 2010-01-15 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CN105963695A (zh) 2008-05-02 2016-09-28 阿塞勒隆制药公司 用于调节血管发生和周细胞包裹的基于alk1拮抗剂的方法和组合物
EP2291401A2 (en) 2008-05-15 2011-03-09 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
KR20110031951A (ko) 2008-06-26 2011-03-29 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ의 길항물질 및 적혈구 수준을 증가시키기 위한 이들의 용도
DK3750552T5 (da) 2008-08-14 2024-08-26 Acceleron Pharma Inc Gdf-fælder
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
KR102170682B1 (ko) 2009-08-13 2020-10-28 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
JP2012238811A (ja) 2011-05-13 2012-12-06 Toshiba Corp 半導体不揮発性記憶装置およびその製造方法
US9809636B2 (en) * 2012-04-06 2017-11-07 Acceleron Pharma Inc. Methods for increasing red blood cell levels comprising administering BMP9
CA2874117C (en) * 2012-07-02 2021-10-12 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical agent comprising anti-bmp9 antibody as active ingredient for treatment of anemia such as renal anemia and cancer anemia
TWI814187B (zh) 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008015383A2 (en) * 2006-07-29 2008-02-07 University College Cardiff Consultants Limited Bmp-9 and bmp-10 and their use in breast and prostate cancer therapies

Also Published As

Publication number Publication date
CA2869474C (en) 2021-08-03
US9809636B2 (en) 2017-11-07
EP3351260B1 (en) 2022-07-13
US10829534B2 (en) 2020-11-10
US20210277082A1 (en) 2021-09-09
AU2021201196A1 (en) 2021-03-11
CA2869474A1 (en) 2013-10-10
WO2013152213A1 (en) 2013-10-10
AU2018202326B2 (en) 2020-11-26
JP2021107453A (ja) 2021-07-29
JP2015514115A (ja) 2015-05-18
US20180186851A1 (en) 2018-07-05
US20200115428A1 (en) 2020-04-16
US20130281371A1 (en) 2013-10-24
EP3351260A1 (en) 2018-07-25
US10344066B2 (en) 2019-07-09
JP2019156858A (ja) 2019-09-19
US11807673B2 (en) 2023-11-07
AU2018202326A1 (en) 2018-04-26
EP2844272A1 (en) 2015-03-11
AU2013243388A1 (en) 2014-10-23
EP2844272A4 (en) 2015-11-04
JP6234993B2 (ja) 2017-11-22
JP2017190344A (ja) 2017-10-19

Similar Documents

Publication Publication Date Title
US11807673B2 (en) Methods and compositions for increasing red blood cells
JP6968917B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
JP6860533B2 (ja) 赤血球レベルを増大させるための、ｇｄｆトラップとエリスロポエチン受容体活性化因子とを組み合わせた使用
JP2020186277A (ja) 無効赤血球生成を処置するための方法および組成物
US20230234998A1 (en) Twisted gastrulation polypeptides and uses thereof
CA2964808C (en) Methods and compositions using gdf15 polypeptides for increasing red blood cells

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KUMAR, RAVINDRA; SURAGANI, NAGA VENKATA SAI RAJASEKHAR AND KNOPF, JOHN

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired